Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

Links shared publicly online about this topic.

1,462
total visits

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene® I.V. (nicardipine hydrochloride) is significantly more effective than intravenous labetalol for the management of blood pressure (BP) in stroke patients.

View full resource at news-medical.net

Tags: Pharma, Beta Blocker, Calcium Channel Blocker, Normodyne, Trandate, Cardene, Cardene SR, Hospitals